Clinical Trial Update: Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) [Phase 3]

View source ↗

Summary

Randomized Phase III trial evaluating intensive chemotherapy with or without dasatinib (Sprycel) in acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: University of Ulm | Conditions: Acute Myeloid Leukemia (AML) | Phase 3 | Status: COMPLETED